Shop Medical Lab Equipment
Abinscience InVivoMAb Anti-Human Complement Component C1s Antibody (TNT003) (HY598010-100ug)
Overview
| Catalog No. | HY598010-100ug |
|---|---|
| Description | Abinscience InVivoMAb Anti-Human C1S Antibody (TNT003)[TNT003] (HY598010-100ug) is a mouse monoclonal
antibody detecting C1 esterase
in ELISA, FCM, Neutralization, WB. Suitable for Human.
HIGHLIGHTS
|
| Species reactivity | Human |
| Applications | ELISA, FCM, Neutralization, WB |
| Host species | Mouse |
| Isotype | IgG2a, kappa |
| Clone ID | TNT003 |
| Clonality | Monoclonal |
| Target | C1 esterase, Complement C1s subcomponent, C1S, Complement component 1 subcomponent s |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >95% as determined by SDS-PAGE. |
| Associated products | pH 7.4 Dilution Buffer |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P09871 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Background | Complement C1s subcomponent is a ~76 kDa protein. Component of the complement C1 complex, a multiprotein complex that initiates the classical pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. C1S is activated following association of the C1 complex with immunoglobulins (IgG or IgM) complexed with antigens to form antigen-antibody complexes on the surface of pathogens. C1S is cleaved and activated by C1R to generate C1s subcomponent heavy and light chains. C1s subcomponent light chain then cleaves and activates C2 and C4, the next components of the classical complement pathway. 1. Lacroix, M. et al. (2001) The Journal of biological chemistry 276, 36233-40. PMID: 11445589
2. Kerr, FK. et al. (2005) The Journal of biological chemistry 280, 39510-4. PMID: 16169853
3. Kerr, MA. et al. (1978) The Biochemical journal 171, 99-107. PMID: 417728
4. Reboul, A. et al. (1979) FEBS letters 103, 156-61. PMID: 467643
5. McRae, BJ. et al. (1981) The Journal of biological chemistry 256, 12362-6. PMID: 6271784
6. Thielens, NM. et al. (1982) FEBS letters 141, 19-24. PMID: 6282646
7. Thielens, NM. et al. (1984) FEBS letters 165, 111-6. PMID: 6319179
8. Nagasawa, S. et al. (1977) Proceedings of the National Academy of Sciences of the United States of America 74, 2998-3001. PMID: 70787
9. Rossi, V. et al. (1998) The Journal of biological chemistry 273, 1232-9. PMID: 9422791
10. Zwarthoff, SA. et al. (2021) Proceedings of the National Academy of Sciences of the United States of America 118. PMID: 34155115
|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Images
SDS-PAGE for InVivoMAb Anti-Human C1S Antibody (TNT003)
Datasheets
InVivoMAb Anti-Human Complement Component C1s Antibody (TNT003).pdf